CLDX — Celldex Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.27bn
- $1.55bn
- $1.55m
Celldex Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025
Brief: Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025
Celldex Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Celldex Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx
U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly
U.S. STOCKS ON THE MOVE-Five Below, QXO, PDD Holdings
MS starts coverage on Celldex, bullish view on company's skin disease treatment
Celldex Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Leerink Partners raises PT on Blueprint Medicines
Brief: Celldex Announces First Patient Dosed In Phase 1 Healthy Volunteer Study Of CDX-622
Celldex Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria
Brief: Celldex Announces Upcoming Late Breaking Oral Presentation Of 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Inducible Urticaria At Acaai 2024
Celldex Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Celldex Therapeutics To Advance CIndU Into Phase 3 Development
Brief: Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop